Volcano to market AngioScore balloon catheter in Japan
This article was originally published in Clinica
Endovascular specialist AngioScore (Fremont, California) has signed up Volcano as the exclusive distributor of its AngioSculpt balloon catheter for coronary indications in Japan. The AngioSculpt catheter is designed to treat both simple and complex lesions, including in-stent restenosis and type C lesions. The device has a Nitinol element, which provides anti-slipping properties while circumferentially dilating plaque. Under the terms of the five-year deal, Volcano Japan will distribute the entire line of AngioSculpt PTCA (percutaneous transluminal coronary angioplasty) scoring balloon catheters and any new, modified or next-generation PTCA products. Full financial terms of the deal were not disclosed. In fiscal 2009, San Diego, California-based Volcano recorded $51.5m in Japanese medtech sales, accounting for around 24% of the company’s overall medical device sales.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals